Medicenna Therapeutics Corp T.MDNA

Alternate Symbol(s): MDNAF

Healthcare Biotechnology

Medicenna Therapeutics Corp. is a Canada-based clinical-stage immunotherapy company. The Company's principal business activity is the development and commercialization of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity, thereby preferentially stimulating cancer-killing effector T cells and NK cells. The Company’s IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials including a Phase IIb trial for recurrent glioblastoma (GBM). The Company’s early-stage Bifunctional SuperKine ImmunoTherapies (BiSKITs) program Targeted Metalloprotease Activated SuperKine (T-MASK) programs are designed to enhance the ability of Superkines to treat immunologically cold tumors.

TSX:MDNA - Post by User

Medicenna Therapeutics Corp > Out with the weak eh .

<< Previous

Bullboard Posts

Next >>

Comment by Galaxym31on Mar 18, 2024 3:48pm

154 Views

Post# 35939005

RE:RE:Out with the weak eh .

I bought this all the way from 1.35 down to .24 when they left Nasdaq which was a good move over a roll back . Made for some cheap stock . If they can outdo Keytruda than blue sky .eh .40 us and above . Let some go today at 1.66 and watch it constantly , very happy with this move up from low 60 cents . Chilliwack BC .

<< Previous

Bullboard Posts

Next >>

Gold vs. bitcoin, where should you invest?